Credit Suisse Ups Gilead Target Ahead Of Earnings

Gilead Sciences ( GILD ) reports earnings after the close of trading Thursday, and Credit Suisse is optimistic about the biotech giant’s first quarter. Analyst Alethia Young and her team reiterated an Outperform rating and raised her price target on Gilead from $116 to $120 today. Young writes that she expects the company to report a clean quarter, with the potential for an upside surprise for revenues. Read More »